new glp-1 drugs in development Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Novo cuts GLP-1 prices 70%,

Nonadherence was determined based on the date of treatment discontinuation with GLP1 RA or metformin, day 90 (index) if no further prescription than the initial was redeemed

The agency's decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for the treatment

Aside from the advantage of having higher appeal to people who are squeamish with needles, oral formulations remove the need for cold chain storage for injectable forms of GLP1R/GIPR/GR agonists , which otherwise must be stored at cold temperatures if not provided in a dry (Tablet/pill) form

I.JavaidS.HameedA.et al (2024)